VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

BV-RVG/RVG
Vaccine Information
  • Vaccine Name: BV-RVG/RVG
  • Target Pathogen: Rabies virus
  • Target Disease: Rabies
  • Vaccine Ontology ID: VO_0004651
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Glycoprotein G gene engineering:
    • Type: Recombinant protein preparation
    • Description: The recombinant baculovirus (BV-RVG/RVG) was pseudotyped with the rabies virus glycoprotein (RVG) and also simultaneously expressed another RVG under the control of the immediate early CMV promoter (Wu et al., 2014).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: Recombinant baculovirus (BV-RVG/RVG) was pseudotyped with the rabies virus glycoprotein (RVG) and also simultaneously expressed another RVG under the control of the immediate early CMV promoter (Wu et al., 2014).
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Mouse Response

  • Vaccination Protocol: Mice were immunized intramuscularly with 1 × 10^8 IFU of BV-VSVG/EGFP, BVRVG/EGFP, or BV-RVG/RVG at 3-week interval (Wu et al., 2014).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: Mice were challenged intracerebrally with 50 mouse 50% lethal doses (50 LD50) of rabies virus CVS-24 (Wu et al., 2014).
  • Efficacy: Mice immunized with BV-RVG/RVG developed higher levels of virus-neutralizing antibodies, and conferred 100% protection against rabies viral challenge (Wu et al., 2014).
References
Wu et al., 2014: Wu Q, Yu F, Xu J, Li Y, Chen H, Xiao S, Fu ZF, Fang L. Rabies-virus-glycoprotein-pseudotyped recombinant baculovirus vaccine confers complete protection against lethal rabies virus challenge in a mouse model. Veterinary microbiology. 2014; 171(1-2); 93-9101. [PubMed: 24793501].